Edward Feener

Chief Scientific Officer, Research
KalVista Pharmaceuticals
Cambridge, Massachusetts, United States

Presentation(s):

• PB0536 - Oral Factor XIIa inhibitor KV998086 protects against FeCl3 induced thrombosis in mice.

  Monday, June 26, 2023
  18:30 – 19:30 ET